Quarter-1 results for FY 2025-2026

Revenue Growth 20pctPat Growth 25pctResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹54.73

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.2%-2.2% vs market

Pharmaceuticals peers, median of 148sector+0.3%-2.3% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 2.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0+0.2-2.2+0.3-2.3

Next day

-2.0+0.2-2.2+0.3-2.3

-3.0+0.9-3.9+0.6-3.6

-4.9+0.1-5.0-0.3-4.6

-6.8+1.6-8.4+0.5-7.3

-8.7+2.8-11.5+0.6-9.2

-8.5+3.0-11.5+0.8-9.2

15d

+16.6+2.8+13.7+0.1+16.5

+27.9+3.1+24.8+1.3+26.6

+18.8+1.4+17.3-1.6+20.4

+56.3+1.4+54.8-4.4+60.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Concord Drugs Ltd reported its Q1 FY26 results for the quarter ended 30 June 2025. Consolidated revenue from operations rose to Rs 1,360.64 lakhs from Rs 1,169.29 lakhs in Q1 FY25, a growth of about 16% year-on-year, while standalone revenue jumped over 110% to Rs 1,338.35 lakhs from Rs 635.32 lakhs. Consolidated profit after tax more than quadrupled to Rs 11.77 lakhs (from Rs 2.73 lakhs), and standalone PAT surged to Rs 11.14 lakhs (from Rs 1.18 lakhs). Basic EPS stood at Rs 0.12 (consolidated) and Rs 0.11 (standalone). The auditor (Pundarikashyam and Associates) issued an unmodified review report with no qualifications or emphasis of matter, and the company confirmed no default on loans or debt securities.

Likely market impact

Strong year-on-year rebound in both revenue and profitability, particularly on a standalone basis, signals improving business momentum and may be viewed positively by shareholders, though absolute earnings remain modest.